Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
US11083718B2 · kind B2 · utility
2Cited by
0References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 28, 2018 |
| Grant date | Aug 10, 2021 |
| Priority date | — |
| Expiry date | Jun 2, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.